Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1335056 | 1.00 | DPP4 (0.62) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL516556 | 1.00 | DPP4 (0.62) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL8651376 | 1.00 | DPP4 (0.62) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL12069803 | 1.00 | DPP4 (0.62) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL14440005 | 1.00 | DPP4 (0.62) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| SCHEMBL16847208 | 1.00 | DPP4 (0.62) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| Hydrochloric Acid SCHEMBL520233 | 0.98 | ALDH1A1 (0.61) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| Hydrochloric Acid SCHEMBL520234 | 0.98 | ALDH1A1 (0.61) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| Hydrochloric Acid SCHEMBL3589482 | 0.98 | ALDH1A1 (0.61) | DPP4ADRA2CKDM4ELMNAADRA2A | |
| Hydrochloric Acid SCHEMBL18765989 | 0.98 | ALDH1A1 (0.61) | DPP4ADRA2CKDM4ELMNAADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1659154-B | Process for the preparation of amine stereoisomers | APSINTERM LLC | 2012-05-30 | — | — | CN | claimed |
| CN-101193869-A | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-06-04 | — | — | CN | claimed |
| EP-1497272-A4 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM LLC (US) | 2007-02-07 | — | — | EP | claimed |
| CN-1659154-A | Process for the preparation of amine stereoisomers | APSINTERM LLC (US) | 2005-08-24 | — | — | CN | claimed |
| US-20050165240-A1 | Method of preparing amine stereoisomers | APSINTERM, LLC | 2005-07-28 | — | — | US | claimed |
| EP-1497272-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | Apsinterm, LLC. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003091207-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM, LLC. (US) | 2003-11-06 | — | — | WO | claimed |
| WO-2026104834-A1 | USE OF A NITROGEN CONTAINING COMPOUND WITH INCREASED WATER REPELLENCY, REDUCED FRICTION, OR IMPROVED VISUAL APPEARANCE, METHOD OF TREATING A SURFACE, COMPOSITION AND TREATED SUBSTRATE | INNOSPEC LIMITED (GB) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104847-A1 | USES AND COMPOSITIONS COMPRISING POLYAMIDES | INNOSPEC LIMITED (GB) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104838-A1 | POLYAMIDES AND CONCENTRATE COMPOSITIONS COMPRISING THE POLYAMIDES | INNOSPEC LIMITED (GB) | 2026-05-21 | — | — | WO | disclosed |
| US-20260078098-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-20250109343-A1 | CORROSION INHIBITOR | INNOSPEC LIMITED (GB) | 2025-04-03 | — | — | US | disclosed |
| EP-0222694-A2 | Microbicides | CIBA-GEIGY AG (CH) | 1987-05-20 | — | — | EP | disclosed |
| US-4639478-A | Bismorpholines, a process for their preparation and their use for protection against hydrolysis | BAYER AKTIENGESELLSCHAFT (DE) | 1987-01-27 | — | — | US | disclosed |
| US-4617387-A | REACTING GLYOXAL WITH AN N-SUBSTITUTED AMINO ALCOHOL | BAYER AKTIENGESELLSCHAFT (DE) | 1986-10-14 | — | — | US | disclosed |
| EP-0137251-A2 | Bismorpholines, process for their preparation and their use as anti-hydrolysis agents | BAYER AG (DE) | 1985-04-17 | — | — | EP | disclosed |
| US-4311840-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-19 | — | — | US | disclosed |
| US-4251660-A | Method for preparing tetrahydroisoquinolines | SMITHKLINE CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4146560-A | HYDROGENATION; COPPER-COBALT-CHROMIUM CATALYST | TEXACO DEVELOPMENT CORP. (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165240-A1 | Method of preparing amine stereoisomers | SRM, TST, SMOX | DPP4 4826/4885ADRA2C 817/4885KDM4E 2935/4885 |
| US-20260078098-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | HTR2C, SLC6A2, HTR1D | DPP4 3132/4885ADRA2C 37/4885KDM4E 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.